Inventor
MEYER GLENN A
US45 patents
⚠️ This page may combine multiple inventors who share the name “MEYER GLENN A”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT
18 patentsUS9801841B2Oct 31, 2017
Controlled release dosage form
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT13 citations92
US9655858B2May 23, 2017
Controlled release dosage form
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT16 citations92
US9585843B2Mar 7, 2017
Controlled release dosage form
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT13 citations92
US9579289B2Feb 28, 2017
Controlled release dosage form
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT14 citations92
US9833412B2Dec 5, 2017
Triple combination release multi-layered tablet
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT9 citations82
US11717483B2Aug 8, 2023
Controlled release dosage form with enhanced pharmacokinetics
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT0 citations62
US11679088B2Jun 20, 2023
Controlled release dosage form
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT0 citations62
US11090281B2Aug 17, 2021
Controlled release dosage form
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT0 citations62
US10987328B2Apr 27, 2021
Controlled release dosage form
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT0 citations62
US10987312B2Apr 27, 2021
Controlled release dosage form with enhanced pharmacokinetics
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT0 citations62
US10610505B2Apr 7, 2020
Controlled release dosage form
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT0 citations51
US10532031B2Jan 14, 2020
Controlled release dosage form with enhanced pharmacokinetics
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT0 citations51
US10471031B2Nov 12, 2019
Controlled release dosage form
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT0 citations51
US10300032B2May 28, 2019
Controlled release dosage form
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT0 citations51
US10213402B2Feb 26, 2019
Controlled release dosage form
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT0 citations51
US10213403B2Feb 26, 2019
Controlled release dosage form
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT0 citations51
US10213404B2Feb 26, 2019
Controlled release dosage form
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT0 citations51
US10172800B2Jan 8, 2019
Controlled release dosage form with enhanced pharmacokinetics
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT0 citations51
OSMOTICA KERESKEDELMI ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG
5 patentsUS10213394B1Feb 26, 2019
Composition and method for treating neurological disease
OSMOTICA KERESKEDELMI ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG7 citations82
US10512617B2Dec 24, 2019
Composition and method for treating neurological disease
OSMOTICA KERESKEDELMI ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG2 citations71
US10500171B2Dec 10, 2019
Composition and method for treating neurological disease
OSMOTICA KERESKEDELMI ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG2 citations71
US10500170B2Dec 10, 2019
Composition and method for treating neurological disease
OSMOTICA KERESKEDELMI ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG1 citations71
US10500172B2Dec 10, 2019
Composition and method for treating neurological disease
OSMOTICA KERESKEDELMI ES SZOLGALTATO KORLATOLT FELELOSSEGU TARSASAG2 citations71
ABBOTT LAB
4 patentsUS5294615AMar 15, 1994
Terazosin polymorph and pharmaceutical composition
ABBOTT LAB43 citations95
US5160742ANov 3, 1992
System for delivering an active substance for sustained release
ABBOTT LAB125 citations95
US5609909AMar 11, 1997
Prolamine coatings for taste masking
ABBOTT LAB28 citations93
US5599556AFeb 4, 1997
Prolamine coatings for taste masking
ABBOTT LAB31 citations93